FLAG with Bortezomib Salvage Therapy in Relapsed/Refractory Childhood Leukemia—A Reliable Bridge to Transplantation with Limited Toxicity

Abstract

Sreedhar Jayakrishnan Cherulil

Relapsed refractory leukemia represents a difficult-to-treat population of patients. The balance between perceived benefit and potential side effects along with the significant financial burden of managing multidrug-resistant sepsis are factors that determine the choice of salvage regimen. Here, we present our experience with the combination of fludarabine, cytarabine, granulocyte-colony stimulating factor with bortezomib. The morphological complete response rate was 58% with 50% of the patients achieving complete remission. With only three patients requiring intensive care unit admission during remission induction, 66.6% of the patients went on to undergo successful hematopoietic stem cell transplantation. Thus, it proved to be a possible, safer alternative to other salvage regimens, while enabling a significant percentage of patients to achieve remission and proceed to allogenic stem cell transplantation.

Keywords

childhood leukemia - FLAG - neutropenia - relapsed leukemia - salvage chemotherapy

Publikationsverlauf

Artikel online veröffentlicht:
11. April 2024

• References

• 1 Ravichandran N, Uppuluri R, Swaminathan VV. et al. FLAG with bortezomib in childhood relapsed/refractory leukemia: remission induction with limited toxicity in the era of multidrug-resistant bacteria. J Pediatr Hematol Oncol 2021; 43 (02) e212-e214
• 2 Hoffman AE, Schoonmade LJ, Kaspers GJ. Pediatric relapsed acute myeloid leukemia: a systematic review. Expert Rev Anticancer Ther 2021; 21 (01) 45-52
• 3 Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 2020; 136 (16) 1803-1812
• 4 Burnett AK, Russell NH, Hills RK. et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31 (27) 3360-3368
• 5 Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998; 102 (03) 647-655
• 6 Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11 (01) 116-124
• 7 Hubeek I, Litvinova E, Peters GJ. et al. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Int J Oncol 2004; 25 (06) 1823-1829
• 8 Horton TM, Whitlock JA, Lu X. et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol 2019; 186 (02) 274-285
• 9 Friedrich P, Lam CG, Kaur G, Itriago E, Ribeiro RC, Arora RS. Determinants of treatment abandonment in childhood cancer: results from a global survey. PLoS One 2016; 11 (10) e0163090
• 10 Messinger Y, Gaynon P, Raetz E. et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010; 55 (02) 254-259
• 11 Bertaina A, Vinti L, Strocchio L. et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol 2017; 176 (04) 629-636
• 12 Roy P, Islam R, Saha D. et al. Efficacy and safety of a bortezomib and reduced-intensity cytarabine-based protocol, TMC ALLR1, for relapsed childhood ALL in India. Br J Haematol 2019; 186 (06) 861-865